/home/corante/public_html/pipeline/ en-us derekb.lowe@gmail.com 2013-05-16T06:55:00-05:00 hourly 1 2000-01-01T12:00+00:00 http://pipeline.corante.com/archives/2013/05/16/the_atlantic_on_drug_rd.php "Can you respond to this tripe?" asked one of the emails that sent along this article in The Atlantic. I responded that I was planning to, but that things were made more complicated by my being extensively quoted in said... 76420@/home/corante/public_html/pipeline/ Drug Development 2013-05-16T06:55:00-05:00 http://pipeline.corante.com/archives/2013/04/29/costing_just_too_much.php There's been a lot of rumbling recently about the price of new cancer drugs (see this article for a very typical reaction). It's a topic that's come up around here many times, as would be only natural - scrolling back... 76376@/home/corante/public_html/pipeline/ Drug Prices 2013-04-29T12:44:48-05:00 http://pipeline.corante.com/archives/2013/04/02/tecfideras_price.php Let us take up the case of Tecfidera, the new Biogen/Idec drug for multiple sclerosis, known to us chemists as dimethyl fumarate. It joins the (not very long) list of industrial chemicals (the kind that can be purchased in railroad-car... 76320@/home/corante/public_html/pipeline/ Drug Prices 2013-04-02T06:41:57-05:00 http://pipeline.corante.com/archives/2013/03/27/the_nih_pfizer_and_senator_wyden.php Senator Ron Wyden (D-Oregon) seems to be the latest champion of the "NIH discovers drugs and Pharma rips them off" viewpoint. Here's a post from John LaMattina on Wyden's recent letter to Francis Collins. The proximate cause of all this... 76306@/home/corante/public_html/pipeline/ Academia (vs. Industry) 2013-03-27T06:50:28-05:00 http://pipeline.corante.com/archives/2013/03/18/glaxosmithklines_ceo_on_the_price_of_new_drugs.php Well, GlaxoSmithKline CEO Andrew Witty has made things interesting. Here he is at a recent conference in London when the topic of drug pricing came up: . . . Witty said the $1 billion price tag was "one of the... 76282@/home/corante/public_html/pipeline/ Business and Markets 2013-03-18T06:31:32-05:00 http://pipeline.corante.com/archives/2012/12/07/pharmaceutical_shortages_in_greece.php If you'd like to see how thoroughly a drug market can be screwed up, have a look at Greece. They're leading the way here as well: Ten years after entering the eurozone, Greece is faced with the herculean challenge of... 76054@/home/corante/public_html/pipeline/ Drug Prices 2012-12-07T09:55:24-05:00 http://pipeline.corante.com/archives/2012/12/03/marcia_angells_interview_i_just_cant.php I have tried to listen to this podcast with Marcia Angell, on drug companies and their research, but I cannot seem to make it all the way through. I start shouting at the screen, at the speakers, at the air... 76041@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2012-12-03T11:22:57-05:00 http://pipeline.corante.com/archives/2012/11/29/when_drug_launches_go_bad.php For those connoisseurs of things that have gone wrong, here's a list of the worst drug launches of recent years. And there are some rough ones in there, such as Benlysta, Provenge, and (of course) Makena. And from an aesthetic... 76034@/home/corante/public_html/pipeline/ Business and Markets 2012-11-29T14:38:45-05:00 http://pipeline.corante.com/archives/2012/10/31/the_coming_battle_over_alzheimers_disease.php Solanezumab is a story that won't go away. Eli Lilly's antibody therapy for Alzheimer's is the subject of a lot of arguing among investors: some people (and I'm one of them) think that there is no strong evidence for its... 75973@/home/corante/public_html/pipeline/ Alzheimer's Disease 2012-10-31T06:57:47-05:00 http://pipeline.corante.com/archives/2012/08/17/good_forum_for_a_response_on_drug_innovation.php I wanted to mention that a version of my first post on the Light/Lexchin article is now up over at the Discover magazine site. And if you've been following the comments to that one and to Light's response here, you'll... 75818@/home/corante/public_html/pipeline/ Drug Prices 2012-08-17T06:37:08-05:00 http://pipeline.corante.com/archives/2012/08/15/a_quick_tour_through_drug_development_reality.php I wanted to let people know that I'm working on a long, detailed reply to Donald Light's take on drug research, but that I'm also looking at a few other publication venues for it. More on this as it develops.... 75811@/home/corante/public_html/pipeline/ Drug Development 2012-08-15T07:24:56-05:00 http://pipeline.corante.com/archives/2012/08/13/donald_light_responds_on_drug_innovation_and_costs.php Here's a response from Prof. Light to my post the other day attacking his positions on drug research. I've taken it out of that comments thread to highlight it - he no longer has to wonder if I'll let people... 75805@/home/corante/public_html/pipeline/ "Me Too" Drugs 2012-08-13T06:43:45-05:00 http://pipeline.corante.com/archives/2012/08/09/getting_drug_research_really_really_wrong.php The British Medical Journal says that the "widely touted innovation crisis in pharmaceuticals is a myth". The British Medical Journal is wrong. There, that's about as direct as I can make it. But allow me to go into more detail,... 75801@/home/corante/public_html/pipeline/ Business and Markets 2012-08-09T10:45:39-05:00 http://pipeline.corante.com/archives/2012/07/30/cancer_drugs_value_for_the_money.php And while we're talking oncology, here's a piece from Luke Timmerman at Xconomy that brings up a lot of tough questions. We've talked about some of these before around here, but everyone who works in oncology drug discovery is going... 75779@/home/corante/public_html/pipeline/ Cancer 2012-07-30T10:29:31-05:00 http://pipeline.corante.com/archives/2012/03/13/nexavar_licensed_by_force_in_india.php India has decided to invoke compulsory licensing, and is approving a local generic company's application to make and sell Bayer's Nexavar (sorafenib). I'm assuming that there's a political dimension to this that I'm not quite following. There must be something... 75520@/home/corante/public_html/pipeline/ Drug Prices 2012-03-13T13:21:27-05:00